Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jul;9(7):1759-1762.
doi: 10.21037/jtd.2017.06.27.

CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application

Federica Zito Marino  1   2 , Marina Accardo  1 , Renato Franco  1
Affiliations
Editorial

CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application

Federica Zito Marino et al. J Thorac Dis. 2017 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Examples of multiplex model of CRISPR-barcoding in NSCLC for cancer therapy application. (A) Multiplex model for NSCLC resistance to EGFR inhibition: example of some resistant mutations to EGFR TKI induced in NSCLC cells using CRISPR-barcoding for in vitro and in vivo studies to assess the effects of the treatment with specific TKI; (B) multiplex model for NSCLC resistance to ALK inhibition: example of some resistant mutations to ALK TKI induced in NSCLC cells using CRISPR-barcoding for in vitro and in vivo studies to assess the effects of the treatment with specific TKI; (C) multiplex model for NSCLC harboring concomitant EGFR/ALK alterations: EGFR L858R, EGFR del exon 19 E746-A750, and ALK-rearrangement induced in NSCLC cells using CRISPR-barcoding for in vitro and in vivo studies to assess the effects of the treatment with specific TKI. CRISPR, clustered regularly interspaced short palindromic repeats; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.
See this image and copyright information in PMC

Comment on

References

    1. Jamal-Hanjani M, Quezada SA, Larkin J, et al. Translational Implications of Tumor Heterogeneity. Clin Cancer Res 2015;21:1258-66. 10.1158/1078-0432.CCR-14-1429 - DOI - PMC - PubMed
    1. Bria E, Pilotto S, Amato E, et al. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget 2015;6:12783-95. 10.18632/oncotarget.3727 - DOI - PMC - PubMed
    1. Turke AB, Zejnullahu K, Wu YL, et al. Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88. 10.1016/j.ccr.2009.11.022 - DOI - PMC - PubMed
    1. Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med 2015;21:440-8. 10.1038/nm.3841 - DOI - PubMed
    1. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods 2013;10:957-63. 10.1038/nmeth.2649 - DOI - PMC - PubMed

LinkOut - more resources